CAR T-cell therapy is a groundbreaking form of immunotherapy revolutionizing cancer treatment, and its recent advancements have been remarkable. However, as the therapy expands across new indications and into earlier lines of therapy, challenges emerge. Finding its place in a well-established standard of care may pose significant hurdles, especially when alternative treatments such as new targeted therapies arise.

During this webinar, IQVIA’s Carolina Ricarte, Offering Development Director and Vladimir Bonevski, Associated Product & Strategy Director will provide unique insights from IQVIA’s market research studies, CAR T-cell Monitor & Oncology retrospective chart reviews, around:

• Latest market developments including the current treatment landscape in in Multiple Myeloma, Follicular Lymphoma and Diffuse Large B-cell Lymphoma
• HCP’s perception on the obstacles to CAR T-cell therapies usage in those diseases

In this session, you will also hear directly from CAR T-cell pioneer, Professor Jérôme Larghero, Director of the MEARY Center, France, recognized for the substantial contributions to CAR T-cell therapy research and applications such as:

• Optimizing CAR T-cell manufacturing processes
• Enhancing persistence and durability of CAR T-cell responses
• Exploring novel CAR T-cell designs
• CAR T-cell therapy: advances in treating hematological malignancies and its challenges
• Current treatment landscape: considering alternatives to CAR T-cell therapy

Speakers

	Jérôme Larghero Director, MEARY Center, France
	Carolina Ricarte Offering Development Director, IQVIA
	Vladimir Bonevski Associate Director, Global Oncology Product & Strategy, IQVIA